Myriad Genetics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Myriad Genetics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Growth Efficiency Ratio: Sales grew 22% in 3 years, but profit fell: $174 less profit per $100 of extra sales. Lower than 90% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-0.9×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Higher than 61% of Healthcare companies in United States.
Cash Locked Ratio
$11For every $100 of sales, $11 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $10 tied up three years earlier.
Less money tied up than 79% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
2/3 · 1/3Sales grew in 2 of the last 3 years; profit grew in 1 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
−$174Sales grew 22% in 3 years, but profit fell: $174 less profit per $100 of extra sales.
Lower than 90% of Healthcare companies in United States.
Asset Productivity Ratio
+22% / -41%In 3 years sales changed by +22% while total assets changed by -41%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
0.3×Debt due within a year is covered 0.3 times by its yearly operating cash.
Higher than 69% of Healthcare companies in United States.
Cash Cushion Ratio
−11%Debt, after subtracting cash, equals 11% of its market value (net debt).
Lower than 79% of Healthcare companies in United States.
Tangible Assets Ratio
71%Of every $100 the company owns, $71 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 60% of Healthcare companies in United States.
Tangible Net Worth Ratio
44%Of every $100 of net worth, $44 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 56% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Myriad Genetics, Inc. made a loss over the last year. Myriad Genetics, Inc. owes $0.52 for every $1 it owns. Myriad Genetics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossMyriad Genetics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
1.81The share price is 1.81 times Myriad Genetics, Inc.'s book value per share, lower than 62% of Healthcare companies in United States.
Market cap
$551 MThe total market value of all of Myriad Genetics, Inc.'s shares at today's price (share price × number of shares), larger than 56% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$304 MWhat Myriad Genetics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$3.18Net worth divided by the number of shares. The share price of $5.76 is 1.8 times this, which is the P/B above.
Return on equity (ROE)
-32.5%Myriad Genetics, Inc. lost 32.5% of its shareholders' money over the last year, higher than 60% of Healthcare companies in United States.
Owes vs Owns
0.52×Myriad Genetics, Inc. owes $0.52 for every $1 it owns (moderate), higher than 59% of Healthcare companies in United States.
Dividend yield
NoneMyriad Genetics, Inc. does not currently pay a dividend.
Revenue growth
-2%Revenue fell 2% in the year to Dec 2025, and grew 7% a year on average over 3 years.
Profit growth
LossMyriad Genetics, Inc. made a loss in each of the last two years.
Profit margin
-44.4%Myriad Genetics, Inc. lost $44 for every $100 of revenue.
Interest cover
Not coveredMyriad Genetics, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net debtMyriad Genetics, Inc. had $60 M more debt than cash (net debt) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Myriad Genetics, Inc.: $551 M ÷ $304 M (30 Jun 2026) = 1.8.
What is Myriad Genetics, Inc.'s return on equity?
Myriad Genetics, Inc. lost 32.5% of its shareholders' money over the last year, higher than 60% of Healthcare companies in United States.
How much does Myriad Genetics, Inc. owe compared with what it owns?
Myriad Genetics, Inc. owes $0.52 for every $1 it owns (moderate), higher than 59% of Healthcare companies in United States.
Does Myriad Genetics, Inc. pay a dividend?
No. Myriad Genetics, Inc. does not currently pay a dividend.
Is Myriad Genetics, Inc.'s revenue growing?
Revenue fell 2% in the year to Dec 2025, and grew 7% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.